Exact Sciences Co. (NASDAQ:EXAS) Position Increased by J.W. Cole Advisors Inc.

J.W. Cole Advisors Inc. raised its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS) by 14.3% during the 4th quarter, Holdings Channel reports. The fund owned 8,582 shares of the medical research company’s stock after purchasing an additional 1,073 shares during the period. J.W. Cole Advisors Inc.’s holdings in Exact Sciences were worth $482,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in EXAS. Huntington National Bank raised its stake in Exact Sciences by 838.1% during the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 352 shares in the last quarter. RPg Family Wealth Advisory LLC bought a new stake in Exact Sciences during the 3rd quarter valued at $34,000. Capital Performance Advisors LLP bought a new stake in Exact Sciences during the 3rd quarter valued at $35,000. Asset Planning Inc bought a new stake in Exact Sciences during the 4th quarter valued at $40,000. Finally, Modus Advisors LLC bought a new stake in Exact Sciences during the 4th quarter valued at $43,000. Institutional investors own 88.82% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on EXAS. Canaccord Genuity Group cut their target price on Exact Sciences from $95.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Stifel Nicolaus lowered their price target on Exact Sciences from $82.00 to $67.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. BTIG Research lifted their price target on Exact Sciences from $65.00 to $75.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Evercore ISI lowered their price target on Exact Sciences from $80.00 to $60.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Finally, Craig Hallum lowered their price target on Exact Sciences from $82.00 to $65.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $72.76.

Exact Sciences Trading Up 1.7 %

Shares of EXAS stock opened at $50.48 on Thursday. Exact Sciences Co. has a 12 month low of $40.62 and a 12 month high of $79.62. The company has a quick ratio of 1.93, a current ratio of 2.12 and a debt-to-equity ratio of 0.72. The business’s 50 day moving average is $55.41 and its two-hundred day moving average is $60.10. The company has a market cap of $9.34 billion, a PE ratio of -43.14 and a beta of 1.24.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative net margin of 7.95% and a negative return on equity of 6.17%. Equities analysts predict that Exact Sciences Co. will post -1.1 EPS for the current year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.